"Dr Reddy's Laboratories: Hold"
"Growth rates in the coming year would be impressive, but it may not be easy for DRL to sustain its performance thereon. While shared FTF launch of generic Geodon and higher contribution from generic Arixtra sales would give a leg up to its revenues, higher competition in its other launches would curtail the growth.
DRL has already garnered 18 per cent market share in generic Arixtra and expects to target the hospital segment once the production stabilises. Generic Arixtra is manufactured using a method developed by Alchemia, and marketed by Dr Reddy's. Only a month ago, Alchemia said that it was selling more than $1.4 million per week worth of the drug in the US market since its launch in July 2011. In end-March, DRL made a regulatory submission covering generic Arixtra in Europe. While the approval is at least a year away, the timely filing provides confidence."
http://www.thehindubusinessline.com/features/investment-world/stock-insight/article3314905.ece
- Forums
- ASX - By Stock
- fondaparinux eu filing
"Dr Reddy's Laboratories: Hold""Growth rates in the coming year...
Featured News
KAI
Pilbara Minerals buys land off Kairos part of its York gold project for $20M – and a 2% royalty on any PLS gold sales
STX
Strike hands $48.5M contract to Clarke Energy to produce 20x 4.5MW gas engines for Sth Erregulla
Add TSN (ASX) to my watchlist
|
|||||
Last
1.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $1.409M |
Open | High | Low | Value | Volume |
0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Featured News
AVH
Avita boosts skin restoration product portfolio with 'dermal matrix' – a kind of next-level gauze made of fake skin
MND
Albemarle lithium downsize burns $200M hole in Monadelphous's pocket as latter's contracts terminated
TSN (ASX) Chart |
Day chart unavailable